ORYZON GENOMICS news, videos and press releases
For more news please use our advanced search feature.
ORYZON GENOMICS - More news...
ORYZON GENOMICS - More news...
- ORYZON Announces First Patient Dosed in NCI-Sponsored Phase I/II Clinical Trial of Iadademstat Plus Immune Checkpoint Inhibitors in 1L Extensive Stage Small Cell Lung Cancer
- ORYZON to Provide Corporate Progress Updates at Several Events in March-April
- Oryzon Announces Publication of Study on Phelan-McDermid Syndrome (PMS) Patients, a Form of Autism, Paving the Way for a Novel Personalized Medicine Approach with Vafidemstat
- Oryzon Defines Phase III Trial Endpoints for Agitation and Aggression in BPD with Input From New Clinical Advisory Board
- ORYZON Announces the Voting Results of February 2025 Extraordinary General Shareholders' Meeting
- ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31, 2024
- ORYZON Announces Journal Publication of Final Phase IIa REIMAGINE Results with Vafidemstat in Psychiatry and Clinical Neurosciences
- ORYZON to Reshape Its Board of Directors at the Upcoming Shareholders’ Meeting
- ORYZON announces first patient dosed in an Investigator-initiated Phase I study of iadademstat in myelodysplastic syndrome
- ORYZON announces appointment of Dr. Pierre Beaurang as Strategy and Business Development Advisor
- ORYZON Announces First Patient Dosed in NCI-Sponsored Iadademstat in Combination With Venetoclax and Azacitidine Clinical Trial in First Line Acute Myeloid Leukemia
- ORYZON to Provide Corporate Progress Updates at Several Events in January-February
-
Oryzon Genomics – executive interview (10 December 2024)
- ORYZON Continues to Strengthen its Patent Portfolio for Vafidemstat
- ORYZON Reports Financial Results and Corporate Update for Quarter Ended September 30, 2024
- ORYZON receives minutes from End-of-Phase II meeting with the FDA on the PORTICO-2 Phase III vafidemstat trial in Borderline Personality Disorder
- ORYZON Presents the Final Data From PORTICO, a Global Phase IIb Vafidemstat Trial in Borderline Personality Disorder (BPD), at the European College of Neuropsychopharmacology (ECNP) Congress
- ORYZON Receives “Intention to Grant” Communication for Patent Relating to the Use of Vafidemstat in Borderline Personality Disorder
- ORYZON Announces First Patient Dosed in an Investigator-Initiated Phase Ib Study of Iadademstat in First-Line Acute Myeloid Leukemia
- ORYZON Continues to Strengthen its Patent Portfolio for Vafidemstat with Additional “Decision to Grant” Communications
- ORYZON to Provide Corporate Progress Updates at Several Events in September
- ORYZON reports financial results and corporate update for half-year ending June 30, 2024
- ORYZON Receives “Decision to grant” for Two Important Patents for Vafidemstat in Japan
- ORYZON Announces Voting Results from its 2024 Annual General Meeting of Shareholders
- ORYZON Announces Presentation of Final Data From PORTICO, Vafidemstat’s Global Phase IIb Trial in Borderline Personality Disorder, at the 37th ECNP Annual Conference
- ORYZON Presents Preliminary Data From Ongoing Phase Ib FRIDA Trial with Iadademstat Plus Gilteritinib in Relapsed/Refractory FLT3-mut AML Patients at EHA-2024
- ORYZON Announces Journal Publication of Final Phase IIa ALICE Results with Iadademstat in The Lancet Hematology
- ORYZON to Provide Corporate Progress Updates at Several Events in June
- ORYZON Selected as Associated Partner in the First Important Project of Common European Interest (IPCEI) in the Health Sector (Med4Cure Project)
- ORYZON to Provide Corporate Progress Updates at Several Events in May
